Expert Interview
Discussing the upcoming phase 3 readout of povorcitinib in Hidradenitis Suppurativa, as well as other investigational agents including upadacitinib and sonelokimab
Ticker(s): INCY, ABBV, MLTXInstitution: Mount Sinai
- Medical Director for Dermatology at Mount Sinai Healthcare System.
- Manages ~100 patients with hidradenitis supportiva & 50 patients with vitiligo.
- Active in both basic science research and clinical trials, serving as the PI in numerous trials encompassing clinical areas such as psoriasis, atopic dermatitis, Hidradenitis suppurativa, and vitiligo.
What are you currently using to treat HS?
Added By: wilson_adminWhat is your opinion on JAKi to treat HS?
Added By: wilson_adminWhat is your opinion on IL-17 to treat HS?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
